RxDoctor Payments DataLook up a doctor →

David Jawahar, MD

Pulmonary Disease · Dover, DENPI 1306828330

Payments from drug & device makers

$9,180in general payments, 2019–2025

Across 437 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$715
  • Sanofi$533
  • Boehringer Ingelheim$460
  • Genentech USA, Inc.$329
  • plus $3K from 31 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,180 in reported general payments places this provider in the 70th percentile of 39 pulmonary disease providers in Delaware.

See all pulmonary disease providers in Delaware

Medicare billing

Part B allowed, 2024
$1,130,613
Medicare patients
2,602
Services billed
19,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →